Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Camptothecin (CPT) analogs that form more stable ternary complexes with DNA and topoisomerase I (termed cleavable complexes) show greater activity in their ability to inhibit tumor cell line growth in preclinical studies. Based on our earlier work, we hypothesized that analogs bearing hydrogen bonding moieties at the 7- through 10-position of CPT would result in more stable cleavable complexes. Consequently, we synthesized analogs with 7-mono-, 7-di-, and 7-trihydroxymethylaminomethyl groups. These analogs showed increasing cleavable complex stability as the number of hydroxyl groups was increased. The 7-trihydroxymethylaminomethyl analog of 10,11-methylenedioxycamptothecin (THMAM-MD) showed remarkable ternary complex stability with a half-life of 116 minutes. This is an order of magnitude more stable than any previously examined analog. Our in vitro analysis demonstrated that these analogs were all potent topoisomerase I poisons and could inhibit tumor cell growth in culture. We studied the effects of THMAM-MD in vivo in severe combined immunodeficient mice bearing HT-29 colon cancer and MiaPaCa-2 pancreatic cancer tumors. The THMAM-MD analog showed excellent, persisting activity in inhibiting tumor growth with both lines. Taken together, our results suggest that CPTs with hydrophilic, hydrogen-bonding groups at the 7-position hold the promise of excellent clinical activity.
Wadkins
Randy M
RM
Department of Chemistry and Biochemistry, University of Mississippi, University, Mississippi 38677, USA. rwadkins@olemiss.edu
Bearss
David
D
Manikumar
Govindarajan
G
Wani
Mansukhlal C
MC
Wall
Monroe E
ME
Von Hoff
Daniel D
DD
D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D045744:Cell Line, Tumor; D004247:DNA / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D004264:DNA Topoisomerases, Type I / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D019073:HT29 Cells; D006367:HeLa Cells; D006801:Humans; D006860:Hydrogen Bonding; D057927:Hydrophobic and Hydrophilic Interactions; D051379:Mice; D016513:Mice, SCID; D008958:Models, Molecular; D013329:Structure-Activity Relationship; D014867:Water / Q000737:chemistry / Q000378:metabolism
C120496:10,11-methylenedioxycamptothecin; D014867:Water; D004247:DNA; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin